Basel, Switzerland, Feb. 03, 2005 (PRIMEZONE) -- Conference Call, 3rd February 2005, 4 p.m. CET (10 a.m. EST) Basilea Enters a Global Collaboration with Johnson & Johnson on Ceftobiprole.
Dear Madam/Sir,
Basilea Pharmaceutica AG, invites you to participate in a conference call on Thursday, February 3rd, 2005 during which Dr. Anthony Man CEO will be joined by Mr. Ronald Scott CFO to provide an update on the company's activities and business outlook related to ceftobiprole (BAL5788), Basilea's first-in-class broad-spectrum anti-MRSA cephalosporin antibiotic following today's announcement of a collaboration with Johnson & Johnson's affiliate Cilag AG International.
The call will be held in English and takes place: Date: Thursday, February 3rd, 2005 Time: 4pm until 5pm (CET) Dial-in numbers: +41 (0) 91 610 56 00 (Europe and ROW) +1 (1) 866 291 4166 (USA) +44 (0) 207 107 0611 (UK)
The playback will be available 1 hour after the conference call for 48 hrs. Participants requesting the Digital Playback will be dialing: +41 91 612 4330 (in Europe) +1 412 317 0088 (in USA) +44 207 1086233 (in UK) and will be asked to enter the ID 143 followed by the # sign.
We would be very pleased if you can join us.
With best regards, Barbara Zink Investor Relations
The Conference Call Invitation can be downloaded from the following link: http://hugin.info/134390/R/978713/144663.pdf